Daré Bioscience FY2025: $24.7M cash, $20.8M equity proceeds; DARE to PLAY revenue expected Q2 2026

Dare Bioscience, Inc.

Cash and cash equivalents $24.7M at Dec 31, 2025; working capital $3.4M.
Received $20.8M net from at-the-market equity program and equity line in 2025.
Non-dilutive funding: $13.6M Gates Foundation, $4.5M ARPA-H, $1.3M NIH in 2025.
SG&A $8.8M (down from $9.2M in 2024); R&D $5.5M (down from $14.3M); contra-R&D $16.4M from grants.
Expects DARE to PLAY product revenue and Flora Sync LF5 consumer revenue to begin Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this report.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-012902

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.